These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21143174)

  • 1. Biomarkers in systemic sclerosis-related pulmonary arterial hypertension.
    Dimitroulas T; Giannakoulas G; Karvounis H; Settas L; Kitas GD
    Curr Vasc Pharmacol; 2011 Mar; 9(2):213-9. PubMed ID: 21143174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natriuretic peptides in systemic sclerosis-related pulmonary arterial hypertension.
    Dimitroulas T; Giannakoulas G; Karvounis H; Gatzoulis MA; Settas L
    Semin Arthritis Rheum; 2010 Feb; 39(4):278-84. PubMed ID: 19539354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Membrane diffusion- and capillary blood volume measurements are not useful as screening tools for pulmonary arterial hypertension in systemic sclerosis: a case control study.
    Overbeek MJ; Groepenhoff H; Voskuyl AE; Smit EF; Peeters JW; Vonk-Noordegraaf A; Spreeuwenberg MD; Dijkmans BC; Boonstra A
    Respir Res; 2008 Oct; 9(1):68. PubMed ID: 18828919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet-derived growth factor receptor-β and epidermal growth factor receptor in pulmonary vasculature of systemic sclerosis-associated pulmonary arterial hypertension versus idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: a case-control study.
    Overbeek MJ; Boonstra A; Voskuyl AE; Vonk MC; Vonk-Noordegraaf A; van Berkel MP; Mooi WJ; Dijkmans BA; Hondema LS; Smit EF; Grünberg K
    Arthritis Res Ther; 2011 Apr; 13(2):R61. PubMed ID: 21492463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic sclerosis-related pulmonary hypertension: unique characteristics and future treatment targets.
    Dimitroulas T; Giannakoulas G; Karvounis H; Settas L; Kitas GD
    Curr Pharm Des; 2012; 18(11):1457-64. PubMed ID: 22364130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis-associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension.
    Argula RG; Karwa A; Lauer A; Gregg D; Silver RM; Feghali-Bostwick C; Schanpp LM; Egbert K; Usher BW; Ramakrishnan V; Hassoun PM; Strange C
    Ann Am Thorac Soc; 2017 May; 14(5):682-689. PubMed ID: 28282243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening patients with scleroderma for pulmonary arterial hypertension and implications for other at-risk populations.
    Schwaiger JP; Khanna D; Gerry Coghlan J
    Eur Respir Rev; 2013 Dec; 22(130):515-25. PubMed ID: 24293467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study.
    Thakkar V; Stevens W; Prior D; Rabusa C; Sahhar J; Walker JG; Roddy J; Lester S; Rischmueller M; Zochling J; Nash P; Gabbay E; Youssef P; Proudman SM; Nikpour M
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):129-136. PubMed ID: 27214686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scleroderma renal crisis accompanied by new-onset pulmonary arterial hypertension: an acute systemic endothelial injury? Case report and literature.
    Dimitroulas T; Sarafidis P; Roma V; Karagiannopoulou G; Kapoulas S; Dimitroula H; Settas L; Lasaridis A
    Inflamm Allergy Drug Targets; 2010 Sep; 9(4):313-8. PubMed ID: 20969543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension.
    Dimitroulas T; Giannakoulas G; Karvounis H; Sfetsios T; Koliakos G; Parcharidis G; Settas L
    Int J Cardiol; 2007 Sep; 121(1):135-7. PubMed ID: 17088004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline.
    Colaci M; Giuggioli D; Sebastiani M; Manfredi A; Lumetti F; Luppi F; Cerri S; Ferri C
    Reumatismo; 2015 Dec; 67(4):149-55. PubMed ID: 27215180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microvascular damage in systemic sclerosis: detection and monitoring with biomarkers.
    Hummers LK
    Curr Rheumatol Rep; 2006 Apr; 8(2):131-7. PubMed ID: 16569372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of screening algorithms in systemic sclerosis-related pulmonary arterial hypertension: a systematic review.
    Thakkar V; Stevens WM; Moore OA; Nikpour M
    Intern Med J; 2013 Jul; 43(7):751-60. PubMed ID: 23611651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular outcome in systemic sclerosis.
    Voilliot D; Magne J; Dulgheru R; Kou S; Henri C; Caballero L; De Sousa C; Sprynger M; Andre B; Pierard LA; Lancellotti P
    Acta Cardiol; 2015 Oct; 70(5):554-63. PubMed ID: 26567815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nailfold capillaroscopic changes in patients with idiopathic pulmonary arterial hypertension and systemic sclerosis-related pulmonary arterial hypertension.
    Corrado A; Correale M; Mansueto N; Monaco I; Carriero A; Mele A; Colia R; Di Biase M; Cantatore FP
    Microvasc Res; 2017 Nov; 114():46-51. PubMed ID: 28619664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated serum levels of macrophage migration inhibitory factor and stem cell growth factor β in patients with idiopathic and systemic sclerosis associated pulmonary arterial hypertension.
    Stefanantoni K; Sciarra I; Vasile M; Badagliacca R; Poscia R; Pendolino M; Alessandri C; Vizza CD; Valesini G; Riccieri V
    Reumatismo; 2015 Mar; 66(4):270-6. PubMed ID: 25829187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic sclerosis complicated by arrhythmogenic right ventricular dysplasia that was misinterpreted as pulmonary arterial hypertension.
    Arai S; Kurasawa K; Maezawa R; Hanaoka R; Fukuda T
    Mod Rheumatol; 2012 Feb; 22(1):152-7. PubMed ID: 21706262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment.
    Attanasio U; Cuomo A; Pirozzi F; Loffredo S; Abete P; Petretta M; Marone G; Bonaduce D; De Paulis A; Rossi FW; Tocchetti CG; Mercurio V
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idiopathic and Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A Comparison of Demographic, Hemodynamic, and MRI Characteristics and Outcomes.
    Ramjug S; Hussain N; Hurdman J; Billings C; Charalampopoulos A; Elliot CA; Kiely DG; Sabroe I; Rajaram S; Swift AJ; Condliffe R
    Chest; 2017 Jul; 152(1):92-102. PubMed ID: 28223154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension.
    Williams MH; Handler CE; Akram R; Smith CJ; Das C; Smee J; Nair D; Denton CP; Black CM; Coghlan JG
    Eur Heart J; 2006 Jun; 27(12):1485-94. PubMed ID: 16682379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.